| Detected | Trial | Change |
|---|---|---|
| 2026-06-04 | NCT07217860 An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) |
Trial sites expanded: 12 -> 15 locations |
| 2026-06-02 | NCT06922110 An Open-Label Study of Azetukalner in Major Depressive Disorder |
Trial sites expanded: 49 -> 63 locations |
| 2026-05-15 | NCT05718817 An Open-label Study of XEN1101 in Epilepsy |
Trial sites expanded: 146 -> 149 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05716100 | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | Focal Onset Seizures | Recruiting |
| NCT07076407 | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | Major Depressive Disorder | Recruiting |
| NCT05667142 | A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic… | Primary Generalized Tonic-Clonic Seizures | Recruiting |
| NCT07172516 | A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With… | Bipolar Disorder | Recruiting |
| NCT05718817 | An Open-label Study of XEN1101 in Epilepsy | Focal Epilepsy | Enrolling by Invitation |
| NCT06922110 | An Open-Label Study of Azetukalner in Major Depressive Disorder | Major Depressive Disorder | Enrolling by Invitation |
| NCT07217860 | An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) | Bipolar Depression | Enrolling by Invitation |